Bioequivalence Study of 2 Sizes of SHR4640 Tablets in Healthy Subjects (Randomized, Open, Single Dose, Two Sequences, Two Cycles, Self-Crossover Control)
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Ruzinurad (Primary)
- Indications Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 21 Jan 2024 Status changed from active, no longer recruiting to completed.
- 18 Dec 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 15 Dec 2023 New trial record